trending Market Intelligence /marketintelligence/en/news-insights/trending/ATaUugWPSy1x2yvb64Ilkg2 content esgSubNav
In This List

Aurinia to raise $166.7M via common stock offering

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Aurinia to raise $166.7M via common stock offering

Aurinia Pharmaceuticals Inc. priced a public offering of its common stock to raise about $166.7 million in gross proceeds.

The Canadian biotechnology company is offering 11,115,165 shares for $15 each. Underwriters will also be given a 30-day option to buy up to an additional 1,667,274 shares from the company.

The offering is expected to close by Dec. 12. Jefferies LLC and SVB Leerink LLC are joint book-running managers, and H.C. Wainwright & Co. LLC, Oppenheimer & Co. Inc. and Bloom Burton Securities Inc. are the co-managers for the offering.

The Victoria, British Columbia-based company plans to use the net proceeds from the offering primarily to prepare for upcoming commercialization and launch activities. Aurinia recently reported positive results for its medicine voclosporin, and plans to seek U.S. regulatory approval for the drug during the first half of 2020.